Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
48 hedge funds and large institutions have $42.2M invested in Provention Bio, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 14 increasing their positions, 3 reducing their positions, and 7 closing their positions.
367% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 3
286% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 7
71% more funds holding
Funds holding: 28 → 48 (+20)
70% more capital invested
Capital invested by funds: $24.8M → $42.2M (+$17.4M)
63% less call options, than puts
Call options by funds: $164K | Put options by funds: $447K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$7.33M |
| 2 |
SCM
Segantii Capital Management
Hong Kong
|
+$7.33M |
| 3 |
PA
Perceptive Advisors
New York
|
+$6.74M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.57M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
-$891K |
| 2 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$582K |
| 3 |
IG
ING Group
Amsterdam,
Netherlands
|
-$467K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$451K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$282K |
PRVB Hedge Fund Activity: Q3 2019 in Review
48 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2019, worth a combined $42.2M — up 70% from $24.8M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new PRVB positions and 7 closed out — a net gain of 20 holders — while 14 added to existing stakes and 3 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $7.33M. The largest seller was Eversept Partners, exiting entirely with an estimated $891K sold.
- 48 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2019, up from 28 in Q2 2019.
- Funds reported $42.2M of Provention Bio, Inc. Common Stock stock for Q3 2019, up 70% quarter-over-quarter.
- 27 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2019 and 7 closed out, a net change of +20 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q3 2019 was Deerfield Management, an estimated $7.33M added.
- The largest Provention Bio, Inc. Common Stock seller in Q3 2019 was Eversept Partners, an estimated $891K sold.
Based on aggregated 13F filings for Q3 2019.